Envoy Medical, Inc. Cash Flow Statement
COCH|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Envoy Medical, Inc. used $18M in operating cash flow and negative free cash flow of $19M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$20.8M | -$29.9M | -$15.9M |
| Depreciation & Amortization | $173.0K | $133.0K | $75.0K |
| Operating Cash Flow | -$17.9M | -$17.1M | -$8.8M |
| Capital Expenditures | $980.0K | $153.0K | $218.0K |
| Free Cash Flow | -$18.9M | -$17.2M | -$9.0M |
| Dividends Paid | $2.4M | $2.4M | - |
| FCF Margin | -8412.9% | -5457.0% | -3807.2% |